Abstract：Objective To explore the changes of peripheral blood T lymphocytes before and after the treatment with cellular immunotherapy in severe aplastic anemia (SAA) patients. Methods We selected 32 SAA patients treated in Guangzhou Development District Hospital from January 2015 to January 2016. Flow cytometry was used to detect T lymphocyte before and after receiving cellular immunotherapy, and routine blood indicators were simultaneously determined. The changes of T lymphocytes before and after the treatment were analyzed. Results After the treatment, the basic cure and remission rate of the 32 SAA patients was 59.37% (19/32). After the treatment, peripheral blood neutrophils, reticulated red blood cell, platelet and lymphocyte of the 19 effective cases were significantly increased as compared with those before the treatment (P<0.05). No obvious changes were found in CD4+ T lymphocyte (%) and CD4+/CD8+ before and after the therapy (both P>0.05), while CD8+ T lymphocyte (%) was significantly increased (P<0.05). The neutrophil-to-lymphocyte ratio was also increased from (0.85±0.23) to (1.89±0.57). Conclusions As for aplastic anemia patients with effective cellular immunotherapy, the neutrophil-to-lymphocyte ratio is reversed, but no change is observed in the CD4+/CD8+ ratio. Cellular immunotherapy can significantly increase the proportion of CD8+T lymphocytes.
[1] Miano M, Dufour C. The diagnosis and treatment of aplastic anemia: a review[J]. Int J Hematol, 2015, 101(6):527-535. [2] Liu HY, Liu TT. Research progress on pathogenesis of aplastic anemia[J]. J Exp Hematol, 2015, 23(4):1216-1220. [3] Jiang BL, Li J P, Li WQ, et al. Role of CD8(+)T cells and their secreted cytokines in the pathogenesis of aplastic anemia[J].J Exp Hematol,2014, 22(2):569-572. [4] Zhu C, Gao Y, Jiang T, et al. Meta-analysis of Huangqi injection for the adjunctive therapy of aplastic anemia[J]. Int J Clin Exp Med, 2015, 8(7):10256-10264. [5] 唐文珏. 免疫调节T细胞在再生障碍性贫血细胞免疫功能紊乱中的作用[J]. 当代医学, 2015, 21(1):87-88. [6] 石秀珍, 王会平, 潘莹,等. CD4+CD25+Treg细胞和T细胞亚群评估再生障碍性贫血患者免疫状态的对比研究[J]. 临床荟萃, 2015,30(6):628-632. [7] 余卫,陈嘉榆,陈玲珍,等.过继细胞免疫疗法治疗重型再生障碍性贫血的临床研究[J]. 广东医学, 2011, 32(13):1688-1690. [8] 张之南, 沈悌. 血液病诊断及疗效标准(第3版)[M].北京: 科学出版社, 2008:58-68. [9] 陈玲珍,陈嘉榆,巫进明,等.特异性免疫细胞治疗原发性再生障碍性贫血的初步探讨[J].广东医学, 2007, 28(1):59-60. [10] Lu T, Yan L, Peng L, et al. Decreased circulating Th22 and Th17 cells in patients with aplastic anemia[J]. Clin Chim Acta, 2015, 450:90-96. [11] Qingqing W, Jizhou Z, Jun S, et al. Increased bone marrow(BM)plasma level of soluble CD30 and correlations with BM plasma level of interferon(IFN)-γ, CD4/CD8 T-cell ratio and disease severity in aplastic anemia[J]. PLoS One, 2014, 9(11):e110787-e110787. [12] 李梅, 陈伟光, 华兴,等. 乳腺浸润性微乳头状癌中浸润淋巴细胞CD4+、CD8+表达与预后的关系[J]. 实用预防医学, 2014, 21(8):969-971. [13] 刘薇薇,陈嘉榆,余卫,等. 细胞因子诱导的免疫细胞治疗苯中毒再生障碍性贫血的临床研究[J]. 中国工业医学杂志中国工业医学杂志,2010, 23(1):13-16.
2016, Vol. 23 
